Stock listing
NASDAQ:TECX Tectonic Therapeutic, Inc. Stock
Home listing (NASDAQ) of Tectonic Therapeutic, Inc.
Follow Tectonic Therapeutic, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:TECX
$20.73 USD -0.31 (-1.5%)
Close on Nov 20, 2026
- Day range
- $20.41 – $21.57 USDNov 20, 2026
- Volume
- 268,829 sharesNov 20, 2026
- Market cap
- $413.5M USDAt the close on Nov 20, 2026 · price × 19.95M shares outstanding
- 52-week range
- $16.77 – $39.53 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $5.34M USDMedian day 188,400 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:TECX · Home | $20.73 USD | -0.31 (-1.5%) | 268,829 | $20.70 | $21.57 | $20.41 | $21.04 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:TECX · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $20.73 | -0.31 | -1.5% | $20.70 | $21.57 | $20.41 | 268,829 | |
| $21.04 | +0.96 | +4.8% | $20.08 | $21.31 | $20.08 | 169,433 | |
| $20.08 | -0.90 | -4.3% | $20.91 | $21.10 | $19.76 | 144,206 | |
| $20.98 | -0.16 | -0.8% | $21.07 | $21.42 | $20.53 | 237,429 | |
| $21.14 | +0.10 | +0.5% | $20.96 | $21.29 | $20.11 | 300,637 | |
| $21.04 | -0.92 | -4.2% | $21.75 | $21.75 | $20.20 | 121,952 | |
| $21.96 | -0.01 | 0.0% | $22.19 | $22.49 | $21.73 | 134,015 | |
| $21.97 | +0.08 | +0.4% | $21.82 | $22.80 | $21.14 | 192,783 | |
| $21.89 | +1.25 | +6.1% | $21.18 | $22.09 | $20.34 | 129,559 | |
| $20.64 | +1.22 | +6.3% | $19.00 | $20.89 | $18.92 | 308,034 | |
| $19.42 | -0.88 | -4.3% | $20.30 | $20.30 | $19.01 | 109,567 | |
| $20.30 | +1.32 | +7.0% | $19.57 | $20.57 | $19.33 | 221,504 | |
| $18.98 | 0.00 | 0.0% | $19.13 | $19.74 | $18.76 | 198,953 | |
| $18.98 | -0.80 | -4.0% | $19.78 | $19.94 | $18.54 | 183,870 | |
| $19.78 | -0.72 | -3.5% | $20.51 | $20.51 | $19.56 | 146,257 | |
| $20.50 | -0.06 | -0.3% | $20.92 | $21.44 | $20.36 | 139,590 | |
| $20.56 | +0.22 | +1.1% | $20.12 | $20.77 | $19.99 | 215,885 | |
| $20.34 | +0.39 | +2.0% | $20.09 | $20.54 | $19.74 | 226,968 | |
| $19.95 | -0.12 | -0.6% | $20.00 | $20.52 | $19.75 | 151,222 | |
| $20.07 | -1.02 | -4.8% | $21.03 | $22.31 | $19.83 | 145,000 | |
| $21.09 | -0.75 | -3.4% | $21.86 | $22.28 | $20.97 | 251,400 | |
| $21.84 | +0.01 | 0.0% | $21.86 | $22.30 | $21.53 | 152,800 | |
| $21.83 | +0.68 | +3.2% | $21.22 | $22.44 | $20.99 | 144,500 | |
| $21.15 | +0.50 | +2.4% | $20.78 | $21.30 | $20.45 | 203,000 | |
| $20.65 | -0.65 | -3.1% | $21.35 | $21.51 | $20.55 | 175,400 | |
| $21.30 | +0.34 | +1.6% | $21.08 | $21.51 | $21.06 | 187,400 | |
| $20.96 | -0.35 | -1.6% | $21.22 | $21.75 | $20.60 | 190,800 | |
| $21.31 | -1.04 | -4.7% | $22.23 | $22.38 | $21.02 | 164,000 | |
| $22.35 | -0.98 | -4.2% | $22.99 | $23.12 | $22.26 | 103,900 | |
| $23.33 | +0.58 | +2.5% | $22.74 | $23.61 | $22.74 | 110,700 | |
| $22.75 | +0.04 | +0.2% | $22.56 | $22.96 | $21.59 | 167,700 | |
| $22.71 | +0.30 | +1.3% | $22.23 | $23.43 | $22.00 | 300,800 | |
| $22.41 | -0.70 | -3.0% | $23.15 | $23.27 | $21.83 | 200,900 | |
| $23.11 | +0.57 | +2.5% | $22.67 | $23.32 | $21.71 | 312,600 | |
| $22.54 | -0.13 | -0.6% | $22.73 | $23.07 | $22.14 | 253,400 | |
| $22.67 | -0.62 | -2.7% | $23.25 | $23.65 | $22.41 | 343,500 | |
| $23.29 | -0.05 | -0.2% | $23.66 | $23.66 | $22.60 | 251,600 | |
| $23.34 | -0.17 | -0.7% | $23.85 | $24.54 | $22.54 | 1,050,100 | |
| $23.51 | -0.16 | -0.7% | $23.54 | $23.99 | $23.13 | 234,800 | |
| $23.67 | -0.45 | -1.9% | $24.19 | $24.66 | $23.55 | 97,000 | |
| $24.12 | -0.86 | -3.4% | $24.85 | $24.86 | $23.06 | 214,400 | |
| $24.98 | -1.52 | -5.7% | $26.56 | $26.58 | $24.20 | 207,400 | |
| $26.50 | -0.13 | -0.5% | $26.83 | $27.58 | $26.21 | 188,600 | |
| $26.63 | -0.37 | -1.4% | $27.35 | $27.35 | $26.31 | 131,800 | |
| $27.00 | -0.21 | -0.8% | $27.30 | $27.59 | $26.38 | 330,600 | |
| $27.21 | -0.70 | -2.5% | $28.15 | $28.71 | $27.11 | 186,800 | |
| $27.91 | -0.60 | -2.1% | $28.50 | $29.23 | $27.68 | 188,400 | |
| $28.51 | -1.20 | -4.0% | $29.71 | $30.02 | $27.95 | 220,900 | |
| $29.71 | +0.66 | +2.3% | $29.39 | $30.73 | $29.38 | 145,000 | |
| $29.05 | +0.44 | +1.5% | $29.03 | $29.40 | $28.56 | 155,000 | |
| $28.61 | -1.87 | -6.1% | $30.06 | $30.32 | $28.40 | 252,400 | |
| $30.48 | +0.08 | +0.3% | $30.18 | $31.00 | $29.81 | 133,400 | |
| $30.40 | -0.35 | -1.1% | $30.32 | $31.41 | $29.96 | 116,600 | |
| $30.75 | +0.83 | +2.8% | $29.85 | $31.12 | $29.74 | 159,300 | |
| $29.92 | -0.46 | -1.5% | $30.68 | $32.52 | $29.45 | 140,400 | |
| $30.38 | -0.84 | -2.7% | $31.22 | $31.80 | $29.77 | 167,300 | |
| $31.22 | +1.28 | +4.3% | $30.00 | $31.97 | $28.96 | 240,700 | |
| $29.94 | -5.68 | -15.9% | $35.67 | $35.67 | $29.78 | 719,000 | |
| $35.62 | -1.08 | -2.9% | $36.11 | $36.96 | $34.95 | 157,800 | |
| $36.70 | +0.73 | +2.0% | $35.76 | $38.00 | $35.55 | 278,100 | |
| $35.97 | -1.74 | -4.6% | $37.41 | $38.85 | $35.76 | 145,200 | |
| $37.71 | +1.24 | +3.4% | $36.52 | $38.12 | $36.52 | 144,458 | |
| $36.47 | -1.16 | -3.1% | $37.28 | $38.25 | $35.50 | 222,280 | |
| $37.63 | +1.58 | +4.4% | $36.42 | $38.23 | $36.38 | 188,600 | |
| $36.05 | -0.99 | -2.7% | $36.51 | $37.23 | $35.68 | 196,800 |
Splits
1 split · NASDAQ:TECX · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-12 | Consolidation |
- Ticker
- NASDAQ:TECX
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 9, 2026
Tectonic Therapeutic to Participate in Upcoming Investor Conferences
Latest deck · Aug 6, 2026
Investor Presentation (August 2026)
Investor deck · 56 slides
Latest news
Tectonic Therapeutic to Participate in Upcoming Investor Conferences
Nov 9, 2026
Closed $21.89 (+6.1%) on Nov 9, 2026
Tectonic Therapeutic Announces Third Quarter 2026 Financial Results and Recent Business Highlights
Nov 5, 2026
Closed $20.64 (+6.3%) on Nov 6, 2026
Tectonic Therapeutic Announces Favorable Phase 1 Safety, Tolerability and PK Results for TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia (HHT)
Sep 29, 2026
Closed $23.34 (-0.7%) on Sep 29, 2026
Tectonic Therapeutic to Participate in the Morgan Stanley Global Healthcare Conference
Sep 3, 2026
Closed $29.92 (-1.5%) on Sep 3, 2026
Tectonic Therapeutic Announces Second Quarter 2026 Financial Results and Recent Business Highlights
Aug 6, 2026
Closed $30.98 (+2.5%) on Aug 7, 2026
Tectonic Therapeutic Completes Enrollment in TX45 APEX Phase 2 Clinical Trial in PH-HFpEF Patients
Jun 10, 2026
Closed $28.05 (-1.8%) on Jun 10, 2026
Tectonic Therapeutic Announces First Quarter 2026 Financial Results and Recent Business Highlights
May 7, 2026
Closed $29.00 (+7.9%) on May 8, 2026
Tectonic Therapeutic Appoints Jessica Chutter to Board of Directors
Apr 23, 2026
Closed $28.54 (+0.4%) on Apr 24, 2026
TD Asset Management Inc. Announces TD ETF Distributions
Mar 19, 2026
Closed $30.83 (-4.1%) on Mar 19, 2026
Issued by another party
Tectonic Therapeutic Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
Feb 26, 2026
Closed $23.93 (+3.5%) on Feb 26, 2026
Tectonic Therapeutic, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 13 in the last 12 months · 67 in all · newest Nov 9, 2026 · oldest 2021
- Decks
- 13 decks · latest Aug 6, 2026
Where Tectonic Therapeutic, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:TECX · Home listing · This page | NASDAQ | United States | USD |
| BOATS:TECX | BOATS | United States | USD |
Valuation
Price/book 1.8× against a median of 3.4×: 3rd lowest of 11 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $178.9M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- 1.8×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 0.95
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Tectonic Therapeutic, Inc. · NASDAQ:TECX | US$413.5M | US$178.9M | n/a | n/a | n/a | 1.8× | n/a | 0.0× | 0.95 |
| Indaptus Therapeutics, Inc. · NASDAQ:INDP | US$433.2M | US$402.6M | n/a | n/a | n/a | 41.9× | n/a | 0.0× | 1.77 |
| LongBio Pharma (Suzhou) Co., Ltd. Class H · HKEX:1779 | US$430.7M | US$402.1M | n/a | n/a | n/a | 20.5× | n/a | 0.0× | n/a |
| Ovid Therapeutics Inc. · NASDAQ:OVID | US$429.7M | US$305.4M | n/a | 210× | n/a | 2.2× | n/a | 0.1× | 1.37 |
| Arvinas, Inc. · NASDAQ:ARVN | US$423.0M | −US$135.0M | n/a | −0.5× | n/a | 0.8× | −3.5% | 0.0× | 1.25 |
| Prothena Corporation plc · NASDAQ:PRTA | US$422.1M | US$157.0M | n/a | 3.0× | n/a | 1.6× | −45.4% | 0.0× | 0.96 |
| TaiMed Biologics Inc. · TPEX:4147 | US$421.4M | US$385.5M | n/a | 20.5× | n/a | 3.8× | −22.4% | 0.1× | n/a |
| CHO Pharma, Inc. · TPEX:6586 | US$413.6M | US$354.2M | n/a | 8,157× | n/a | 5.7× | n/a | 0.0× | n/a |
| Jacobio Pharmaceuticals Group Co., Ltd. · HKEX:1167 | US$401.1M | US$173.5M | n/a | 22.2× | n/a | 2.0× | −272.7% | 0.1× | n/a |
| Candel Therapeutics, Inc. · NASDAQ:CADL | US$395.4M | US$193.8M | n/a | n/a | n/a | 3.0× | n/a | 0.0× | 2.03 |
| Ever Supreme Bio Technology Co., Ltd. · TPEX:6712 | US$394.8M | US$362.8M | 27.5× | 11.1× | 23.9× | 4.6× | 43.8% | 0.0× | n/a |
| Median of the others | US$421.7M | US$329.8M | 27.5× | 20.5× | 23.9× | 3.4× | −22.4% | 0.0× | 1.37 |
Forecasts
8 strong buy · 1 buy · 1 hold · Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.
- Price target
- 71.00 USD · Analysts' mean
- EPS, year to Dec 2026
- -5.77 · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Alise Reicin | President and CEO, Director |
| Daniel Lochner | Chief Financial Officer |
| Geraldine Peters-Wiles | Senior Vice President, Human Resources |
| Mary West | Senior Vice President, Clinical Development Operations |
| Washington Alves | Senior Vice President, Technical Operations |
| Marc Schwabish | Chief Business Officer |
| Marcella K Ruddy | Chief Medical Officer |
| Peter McNamara | Chief Scientific Officer |
| Timothy A. Springer | Co-Founder |
Board
| Director | Role |
|---|---|
| François Nader | Chair, Board of Directors |
| Alise Reicin | President and CEO, Director |
| Jessica Chutter | Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 5, 2026 · After close | +6.3% |
| Q2 2026 | Aug 6, 2026 · After close | +2.5% |
| Q1 2026 | May 7, 2026 · After close | +7.9% |
| Q4 2025 | Feb 26, 2026 | +1.5% |
| Q3 2025 | Nov 6, 2025 · After close | +1.7% |
| Q2 2025 | Aug 7, 2025 · After close | +1.8% |
| Q1 2025 | May 8, 2025 · After close | −6.0% |
| Q4 2024 | Mar 12, 2025 · After close | −4.5% |
| Q3 2024 | Nov 7, 2024 · After close | −3.0% |
| Q2 2024 | Aug 14, 2024 · After close | +5.2% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 9, 2024 | −2.4% |
| Q4 2023 | Mar 20, 2024 | −0.8% |
| Q3 2023 | Nov 9, 2023 | −9.9% |
| Q2 2023 | Aug 10, 2023 | +0.7% |
| Q1 2023 | May 11, 2023 | −5.3% |
| Q4 2022 | Mar 23, 2023 | −20.7% |
| Q3 2022 | Nov 8, 2022 | −1.4% |
| Q2 2022 | Aug 9, 2022 | +5.0% |
| Q1 2022 | May 10, 2022 | −7.5% |
| Q4 2021 | Mar 17, 2022 | +11.1% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (August 2026) | Investor deck | 56 slides | Aug 6, 2026 |
| Technical Presentation (February 2026) | Technical | 47 slides | Feb 24, 2026 |
| Technical Presentation (October 2025) | Technical | 13 slides | October 2025 |
| Investor Presentation (August 2025) | Investor deck | 52 slides | Aug 7, 2025 |
| Technical Presentation (May 2025) | Technical | 14 slides | May 17, 2025 |
| Investor Presentation (January 2025) | Investor deck | 39 slides | Jan 13, 2025 |
| Technical Presentation (January 2025) | Technical | 23 slides | January 2025 |
| Technical Presentation (December 2024) | Technical | 36 slides | Dec 12, 2024 |
| Investor Presentation (September 2024) | Investor deck | 56 slides | Sep 19, 2024 |
| Investor Presentation (July 2024) | Investor deck | 56 slides | Jul 30, 2024 |
All 13 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| AVROBIO — Merger or Acquisition (April 2024) | Merger or acquisition | 33 slides | Apr 4, 2024 |
| Merger or Acquisition (April 2024) | Merger or acquisition | 33 slides | April 2024 |
| Merger or Acquisition (January 2024) | Merger or acquisition | 33 slides | January 2024 |
Financings
| Raise | Date |
|---|---|
| Private placement of shares of common stock Announced: about US$185M · US$50 a share · TD Cowen +3 Dealers: TD Cowen, Leerink Partners, Piper Sandler, Wells Fargo Securities Buyers: Adage Capital Partners LP; Ally Bridge Group; Deep Track Capital; EcoR1 Capital; Farallon Capital Management, L.L.C. (funds managed by Farallon Capital Management, L.L.C.); Soleus Capital; StemPoint Capital LP; TAS Partners; Woodline Partners LP Insiders: Individual investors that are officers or directors of Tectonic pay $54.14 per share Use of proceeds: Clinical development of TX45 and TX2100, discovery platform development, working capital and general corporate purposes | Feb 3, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Went public as AvroBio, Inc. Priced at US$19.00 a share on Jun 20, 2018.
- Price
- US$19.00 a share
- Shares offered
- 5,247,958 shares of common stock
- Offering size
- US$99.7 million
- Underwriters' option
- Up to 787,193 more shares
- Underwriters
- MORGAN STANLEY, COWEN, WELLS FARGO SECURITIES, WEDBUSH PACGROW · In the order on the cover
- Shares delivered
- On or about Jun 25, 2018
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Apr 6, 2018 |
| Filed publicly | May 25, 2018 |
| Amended 3 times | Newest Jun 18, 2018 |
| Shares registered with an exchange | Jun 18, 2018 |
| Declared effective by the SEC | Jun 20, 2018 |
| Final prospectus, with the price | Jun 21, 2018 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Jun 21, 2018 |
| EFFECT · Notice that a registration is effective | Jun 20, 2018 |
| S-1MEF · Registration of more shares for the same offering | Jun 20, 2018 |
| CERT · Exchange's certificate of listing | Jun 19, 2018 |
| 8-A12B · Registration of shares for listing on an exchange | Jun 18, 2018 |
| CORRESP · Letter to the SEC | Jun 18, 2018 |
| CORRESP · Letter to the SEC | Jun 18, 2018 |
| S-1/A · Registration statement, amended | Jun 18, 2018 |
| CORRESP · Letter to the SEC | Jun 15, 2018 |
| UPLOAD · Letter from the SEC | Jun 14, 2018 |
All 21 filings
| Filing | Filed |
|---|---|
| UPLOAD · Letter from the SEC | Jun 12, 2018 |
| S-1/A · Registration statement, amended | Jun 11, 2018 |
| CORRESP · Letter to the SEC | Jun 1, 2018 |
| S-1/A · Registration statement, amended | Jun 1, 2018 |
| CORRESP · Letter to the SEC | May 25, 2018 |
| S-1 · Registration statement | May 25, 2018 |
| UPLOAD · Letter from the SEC | May 23, 2018 |
| DRSLTR · Letter to the SEC with a draft | May 11, 2018 |
| DRS/A · Draft registration statement, amended | May 11, 2018 |
| UPLOAD · Letter from the SEC | May 7, 2018 |
| DRS · Draft registration statement | Apr 6, 2018 |
Open IPO · From the cover of the final prospectus (424B4) filed Jun 21, 2018
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | |||||
| Cost of revenue | 1.65M | 617.0K | 4.17M | 1.40M | 1.21M | 850.0K | 380.0K | 45.0K | ||
| Gross profit | -1.65M | -617.0K | -4.17M | -1.40M | -1.21M | -850.0K | -380.0K | -45.0K | ||
| Research and development | 63.5M | 41.4M | 37.0M | 72.2M | 83.1M | 87.2M | 55.0M | 35.1M | 15.2M | 2.66M |
| Selling, general and administrative | 20.5M | 16.7M | 7.68M | 7.18M | 4.63M | |||||
| Operating income | -84.0M | -58.0M | -44.6M | -105.4M | -118.8M | -120.2M | -75.8M | -46.2M | -18.4M | -4.63M |
| Depreciation and amortization | 1.38M | 1.65M | 1.48M | 1.44M | 1.40M | 1.21M | 850.0K | 380.0K | 45.0K | |
| EBITDA | -82.7M | -56.4M | -43.2M | -104.0M | -117.4M | -119.0M | -75.0M | -45.9M | -18.3M | |
| Interest expense | 63.0K | 107.0K | 152.0K | 1.81M | 203.0K | |||||
| Income before tax | -72.9M | -58.0M | -42.8M | -32.2M | -8.93M | -119.7M | -73.0M | -46.4M | -18.6M | -4.66M |
| Income tax | 1.23M | 0 | 0 | 0 | ||||||
| Net income | -74.2M | -58.0M | -42.8M | -105.9M | -119.1M | -119.7M | -73.0M | -46.4M | -18.6M | -4.66M |
| Earnings per share, basic | -4.05 | -6.83 | -33.76 | -2.42 | -2.78 | -3.31 | -2.66 | -3.62 | -8.38 | -2.34 |
| Earnings per share, diluted | -4.05 | -6.83 | -33.76 | -2.42 | -2.78 | -3.31 | -2.66 | -3.62 | -8.38 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 253.8M | 141.2M | 28.8M | 92.6M | 189.6M | 259.7M | 187.0M | 126.3M | 5.96M | 5.36M |
| Receivables | 269.0K | 2.70M | 2.56M | 2.14M | 1.54M | |||||
| Current assets | 257.4M | 146.9M | 30.9M | 100.0M | 199.1M | 267.2M | 195.7M | 130.0M | 6.31M | 5.38M |
| Property, plant and equipment | 1.19M | 2.15M | 3.12M | 2.89M | 4.13M | 3.06M | 3.70M | 2.63M | 349.0K | |
| Total assets | 261.0M | 152.9M | 39.4M | 103.9M | 203.8M | 271.2M | 200.5M | 133.5M | 7.02M | 5.40M |
| Accounts payable | 1.09M | 976.0K | 409.0K | 384.0K | 3.49M | 2.68M | 3.95M | 2.78M | 527.0K | 340.0K |
| Current liabilities | 9.67M | 11.6M | 40.9M | 13.1M | 19.4M | 16.6M | 14.0M | 10.6M | 2.63M | 891.0K |
| Total debt | 1.28M | 3.30M | 4.34M | 15.0M | 15.0M | |||||
| Total liabilities | 9.71M | 12.1M | 43.4M | 28.6M | 34.4M | 16.9M | 14.5M | 11.3M | 3.66M | 979.0K |
| Shareholders' equity | 251.3M | 140.8M | -84.6M | -45.7M | 169.5M | 254.3M | 186.0M | 122.2M | -23.1M | 4.42M |
| Shares outstanding | 18.7M | 14.9M | 1.41M | 43.9M | 43.7M | 43.7M | 31.6M | 23.8M | 2.31M | 1.99M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -60.1M | -59.1M | -40.7M | -97.2M | -98.0M | -98.8M | -67.7M | -37.6M | -16.4M | -3.31M |
| Capital spending | -208.0K | -156.0K | -279.0K | -267.0K | -2.46M | -1.18M | -1.58M | -1.83M | -383.0K | 0 |
| Free cash flow | -60.3M | -59.2M | -41.0M | -97.5M | -100.5M | -100.0M | -69.3M | -39.5M | -16.8M | -3.31M |
| Cash from investing | -138.0K | -156.0K | -279.0K | -267.0K | -2.46M | -1.18M | -1.58M | -1.83M | -383.0K | -24.0K |
| Cash from financing | 173.4M | 171.7M | 33.7M | 262.0K | 30.4M | 172.6M | 130.0M | 160.3M | 17.4M | 8.70M |
| Change in cash | 113.0M | 112.5M | -7.20M | -97.2M | -70.1M | 72.6M | 60.7M | 120.8M | 606.0K | 5.36M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-Q · Quarterly report | Nov 5, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 5, 2026 | Acquisition or disposal | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 29, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 30, 2026 | Other filings | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Sep 29, 2026 | Current report | SEC |
| 4 · Change in ownership | Sep 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 8, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 27, 2026 | Other filings | SEC |
| 4 · Change in ownership | Aug 26, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 21, 2026 | Other filings | SEC |
| 4 · Change in ownership | Aug 14, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 12, 2026 | Other filings | SEC |
| 10-Q · Quarterly report | Aug 6, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 6, 2026 | Results | SEC |
| 4 · Change in ownership | Jul 1, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 30, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 10, 2026 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 10, 2026 | Insider trade | SEC |
| 8-K · Current report | May 7, 2026 | Results | SEC |
| 10-Q · Quarterly report | May 7, 2026 | Quarterly report | SEC |
| 4 · Change in ownership | May 6, 2026 | Insider trade | SEC |
| ARS · Annual report to shareholders | Apr 24, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 24, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 24, 2026 | Meeting notice | SEC |
| 8-K · Current report | Apr 23, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Apr 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 3, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 9, 2026 | Insider trade | SEC |
| S-8 POS | Mar 9, 2026 | Offer document | SEC |
| 144 · Notice of proposed sale | Mar 6, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 6, 2026 | Other filings | SEC |
| 4 · Change in ownership | Mar 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2026 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Mar 5, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 4, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 3, 2026 | Other filings | SEC |
| S-8 · Registration statement for employee plans | Feb 27, 2026 | Offer document | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 27, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Feb 26, 2026 | Results | SEC |
| 10-K · Annual report | Feb 26, 2026 | Annual report | SEC |
| 8-K · Current report | Feb 24, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Feb 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 10, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Jan 29, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Dec 29, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 6, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 6, 2025 | Results | SEC |
| 8-K · Current report | Oct 29, 2025 | Current report | SEC |
| 4 · Change in ownership | Sep 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 29, 2025 | Insider trade | SEC |
| 8-K · Current report | Aug 7, 2025 | Results | SEC |
| 10-Q · Quarterly report | Aug 7, 2025 | Quarterly report | SEC |
| EFFECT · Notice that a registration is effective | Jul 16, 2025 | Other filings | SEC |
| 424B3 · Prospectus | Jul 15, 2025 | Offer document | SEC |
| CORRESP · Letter to the SEC | Jul 11, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jul 10, 2025 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Jul 9, 2025 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Jul 9, 2025 | Other filings | SEC |
| POS AM · Amendment to an effective registration | Jul 7, 2025 | Offer document | SEC |
| POS AM · Amendment to an effective registration | Jul 7, 2025 | Offer document | SEC |
| S-3 · Registration statement | Jul 7, 2025 | Offer document | SEC |
| 4 · Change in ownership | Jun 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2025 | Insider trade | SEC |
| 424B5 · Prospectus | Jun 11, 2025 | Offer document | SEC |
| 424B5 · Prospectus | Jun 11, 2025 | Offer document | SEC |
| 8-K · Current report | Jun 6, 2025 | Meeting outcome | SEC |
| 424B5 · Prospectus | May 19, 2025 | Offer document | SEC |
| 424B5 · Prospectus | May 19, 2025 | Offer document | SEC |
| 8-K · Current report | May 19, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 12, 2025 | Big-stake notice | SEC |
| 424B3 · Prospectus | May 8, 2025 | Offer document | SEC |
| 424B3 · Prospectus | May 8, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | May 8, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 8, 2025 | Results | SEC |
| ARS · Annual report to shareholders | Apr 25, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 25, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 25, 2025 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 9, 2025 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Apr 7, 2025 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Apr 7, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Apr 7, 2025 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Apr 7, 2025 | Big-stake notice | SEC |
| EFFECT · Notice that a registration is effective | Apr 4, 2025 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Apr 3, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Mar 31, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Mar 31, 2025 | Other filings | SEC |
| POS AM · Amendment to an effective registration | Mar 27, 2025 | Offer document | SEC |
| S-1 · Registration statement | Mar 26, 2025 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Mar 20, 2025 | Offer document | SEC |
| 10-K · Annual report | Mar 20, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 20, 2025 | Results | SEC |
| D | Feb 14, 2025 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 13, 2025 | Big-stake notice | SEC |
| 424B5 · Prospectus | Feb 12, 2025 | Offer document | SEC |
| 424B5 · Prospectus | Feb 12, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Feb 12, 2025 | Offer document | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 10, 2025 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Feb 10, 2025 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Feb 7, 2025 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Feb 7, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 6, 2025 | Insider trade | SEC |
| 8-K · Current report | Feb 3, 2025 | Material contract | SEC |
| 8-K · Current report | Jan 30, 2025 | Current report | SEC |
| 4 · Change in ownership | Jan 29, 2025 | Insider trade | SEC |
| 8-K · Current report | Jan 13, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 8, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Dec 11, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 5, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 12, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 7, 2024 | Results | SEC |
| SC 13D/A · Big-stake notice, amended | Oct 28, 2024 | Big-stake notice | SEC |
| SC 13D/A · Big-stake notice, amended | Oct 24, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 24, 2024 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Sep 26, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Sep 26, 2024 | Insider trade | SEC |
| 8-K · Current report | Sep 19, 2024 | Current report | SEC |
| S-8 POS | Aug 27, 2024 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Aug 21, 2024 | Offer document | SEC |
| 8-K · Current report | Aug 14, 2024 | Results | SEC |
| 424B3 · Prospectus | Aug 14, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 14, 2024 | Quarterly report | SEC |
| EFFECT · Notice that a registration is effective | Jul 31, 2024 | Other filings | SEC |
| 424B5 · Prospectus | Jul 30, 2024 | Offer document | SEC |
| 8-K · Current report | Jul 30, 2024 | Current report | SEC |
| 424B3 · Prospectus | Jul 30, 2024 | Offer document | SEC |
| CORRESP · Letter to the SEC | Jul 26, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jul 26, 2024 | Other filings | SEC |
| SC 13G/A · Big-stake notice, amended | Jul 22, 2024 | Big-stake notice | SEC |
| S-1 · Registration statement | Jul 19, 2024 | Offer document | SEC |
| SC 13G · Big-stake notice | Jul 10, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Jul 5, 2024 | Management or board change | SEC |
| SC 13G · Big-stake notice | Jul 1, 2024 | Big-stake notice | SEC |
| SC 13D · Big-stake notice | Jun 27, 2024 | Big-stake notice | SEC |
| SC 13D · Big-stake notice | Jun 26, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Jun 25, 2024 | Current report | SEC |
| SC 13D · Big-stake notice | Jun 25, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 25, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 24, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 24, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 24, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 24, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 24, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 24, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 24, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2024 | Insider trade | SEC |
This page holds 200 of 582 filings. Open Filings
Cap table
Built by 6ix from Tectonic Therapeutic, Inc.’s releases · as of Oct 30, 2026
- Common shares
- 19,948,037
- Fully diluted
- 19,948,037
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 19,948,037 | Oct 30, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Oct 30, 2026 | 19,948,037 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Ian T. Clark Other companies: Takeda Pharmaceutical Co. Ltd. (Director · Since at least Mar 18, 2026); BioMarin Pharmaceutical Inc. (Chair of the Board, · Since at least Aug 1, 2025); GoodRx Holdings, Inc. (Director · Since at least Jul 8, 2024); Kyverna Therapeutics, Inc. (Independent Director · Since at least Feb 7, 2024); Olema Pharmaceuticals, Inc. (Director · Since at least Aug 12, 2020); Guardant Health, Inc. (Director · Since at least Oct 3, 2018); Corvus Pharmaceuticals, Inc. (Director · Since at least Jan 3, 2017); Forty Seven Inc (Director · Jun 27, 2018 – Apr 7, 2020 · Past); Kite Pharma Inc (Director · Jan 3, 2017 – Oct 3, 2017 · Past); Agios Pharmaceuticals, Inc. (Director · Dec 30, 2016 – May 20, 2022 · Past); Terravia Holdings Inc (Director · May 26, 2011 – May 22, 2017 · Past); Dendreon Corp (Director · Oct 7, 2009 – Aug 20, 2010 · Past); Genentech Inc (EVP-COMMERCIAL · Sep 20, 2006 – Mar 26, 2009 · Past) | Director · Jun 20, 2018 – Jun 6, 2023 · Past |
| Terrance McGuire Other companies: Invivyd, Inc. (Director · Since at least Aug 5, 2021); Seer, Inc. (Director · Since at least Dec 3, 2020); Cyclerion Therapeutics, Inc. (Director · Apr 1, 2019 – Nov 30, 2023 · Past); Alector, Inc. (Director · Feb 6, 2019 – Sep 11, 2023 · Past); X4 Pharmaceuticals, Inc. (Director · Nov 15, 2017 – Jun 5, 2018 · Past); Pulmatrix, Inc. (Director · Jun 15, 2015 – May 16, 2019 · Past); Trevena, Inc. (Director · Jan 30, 2014 – May 14, 2014 · Past); Acceleron Pharma Inc (Director · Sep 18, 2013 – Mar 2, 2017 · Past); Ironwood Pharmaceuticals, Inc. (Director · Jun 3, 2013 – Apr 1, 2019 · Past) | Director · Since at least Jun 20, 2024 |
| François Nader Other companies: Moderna, Inc. (Director · Since at least Dec 10, 2019); Tourmaline Bio Inc. (Director · May 6, 2021 – Jun 13, 2023 · Past); Prevail Therapeutics Inc (Director · Jun 19, 2019 – Jan 22, 2021 · Past); Alexion Pharmaceuticals Inc (Director · Nov 15, 2017 – Jul 21, 2021 · Past); Baxalta Inc (Director · Jul 27, 2015 – Jun 3, 2016 · Past); Acceleron Pharma Inc (Director · Dec 11, 2014 – Nov 19, 2021 · Past); Trevena, Inc. (Director · Jan 30, 2014 – May 20, 2015 · Past); NPS Pharmaceuticals Inc (President, CEO and Director, Director · Apr 8, 2013 – Feb 21, 2015 · Past) | Chair, Board of Directors · Since at least Feb 23, 2026 |
| Annalisa Jenkins Other companies: Skye Bioscience, Inc. (Director · Since at least Feb 29, 2024); Mereo BioPharma Group plc (Director · Since at least Jan 1, 2024); COMPASS Pathways Plc (Director · Since at least Jan 1, 2022); Serina Therapeutics, Inc. (Director · Nov 27, 2018 – Jun 21, 2021 · Past); Dimension Therapeutics (President and CEO, Director · Oct 21, 2015 – Nov 7, 2017 · Past); Ardelyx, Inc. (Director · Apr 20, 2015 – Jun 13, 2019 · Past) | Director · Jun 20, 2018 – Jun 6, 2023 · Past |
| Phillip Donenberg Other companies: Sensei Biotherapeutics, Inc. (Chair of the Audit Committee · Since at least Feb 13, 2026); Taysha Gene Therapies, Inc. (Director · Since at least Sep 23, 2020); Depomed Inc (SVP and CFO · Jul 16, 2018 – Jul 16, 2018 · Past); AveXis Inc (Chief Financial Officer · Oct 19, 2017 – May 15, 2018 · Past); CervoMed Inc. (Director · May 27, 2014 – Jul 24, 2014 · Past); ANI Pharmaceuticals, Inc. (Sr VP of Finance, CFO, Secy · Mar 16, 2006 – Jan 25, 2012 · Past) | Director · Since at least Jun 20, 2018 |
| Alise Reicin Other companies: Immatics N.V. (Director · Since at least Mar 18, 2026); Sana Biotechnology, Inc. (Director · Since at least Feb 3, 2021); Q32 Bio Inc. (Director · Jul 11, 2019 – Jun 14, 2023 · Past); Celgene Corporation (PRES., GLOBAL CLINICAL DEV. · Nov 1, 2018 – Nov 20, 2019 · Past) | President and CEO, Director · Since at least Jun 20, 2024 |
| Bruce Booth Other companies: Sionna Therapeutics, Inc. (Director · Since at least Feb 6, 2025); Vigil Neuroscience Inc (Director · Since at least Jan 6, 2022); Kymera Therapeutics, Inc. (Director · Since at least Mar 12, 2021); Dianthus Therapeutics, Inc. (Director · Jun 1, 2021 – Jun 28, 2022 · Past) | Director · Jun 10, 2021 – Jun 6, 2023 · Past |
| Praveen Tipirneni Other companies: BridgeBio Oncology Therapeutics, Inc. (Non-Executive Director · Since at least Aug 11, 2025); Panacea Acquisition II Corp (Director · Apr 6, 2021 – Apr 6, 2021 · Past); Morphic Holding Inc (President and CEO, Director · Jun 26, 2019 – Aug 16, 2024 · Past) | Director · Since at least Jun 20, 2024 |
| Scott Requadt Other companies: ESSA Pharma Inc (Director · Since at least Oct 1, 2020); Tourmaline Bio Inc. (Chief Executive Officer, Director · May 6, 2021 – Feb 1, 2023 · Past); VBI Vaccines Inc. (Director · Dec 31, 2016 – Jan 31, 2019 · Past) | Director · Jun 20, 2018 – Jun 25, 2018 · Past |
| Deanna M Petersen Other companies: Tecogen Inc. (Director · Dec 31, 2017 – Jul 9, 2020 · Past); American DG Energy Inc (Director · Dec 1, 2014 – May 23, 2017 · Past) | Chief Business Officer · Mar 4, 2020 – Feb 8, 2023 · Past |
All 24 people
| Person | Seat |
|---|---|
| Gail M Farfel Other companies: Durect Corporation (Director · Since at least May 9, 2022); ProMIS Neurosciences Inc. (Chief Executive Officer, Director · Sep 19, 2022 – Aug 23, 2023 · Past) | Director · Jun 8, 2022 – Jun 6, 2023 · Past |
| Marcella Kuhlman Ruddy Other companies: Sionna Therapeutics, Inc. (Director · Since at least Feb 6, 2025); Upstream Bio, Inc. (Chief Medical Officer, Tectonic Therapeutic · Since at least Oct 10, 2024) | Chief Medical Officer · Since at least Jun 20, 2024 |
| Stefan Vitorovic Other companies: Vigil Neuroscience Inc (Director · Since at least Jun 9, 2022); Praxis Precision Medicines, Inc. (Director · May 26, 2022 – May 26, 2022 · Past) | Director · Since at least Jun 20, 2024 |
| Birgitte Volck Other companies: Soleno Therapeutics, Inc. (Director · Since at least Jun 10, 2019) | President of R&D · Dec 17, 2018 – Mar 4, 2020 · Past |
| Christian Cortis Other companies: Agenus Inc. (Chief Strategy Officer · Jun 19, 2019 – Jul 23, 2019 · Past) | Chief Operating Officer · Jun 20, 2024 – Jun 20, 2024 · Past |
| Daniel Lochner Other companies: Oyster Point Pharma Inc (Chief Financial Officer · Oct 30, 2019 – Dec 1, 2022 · Past) | Chief Financial Officer · Since at least Jun 20, 2024 |
| Erik Ostrowski Other companies: Akebia Therapeutics, Inc. (Senior Vice President, Chief Financial Officer and Chief Business Officer · Since at least Jun 24, 2024) | Interim CEO, President and CFO · Jan 2, 2019 – Feb 1, 2024 · Past |
| Geoffrey Mackay Other companies: Tourmaline Bio Inc. (Director · May 6, 2021 – Jun 13, 2023 · Past) | President & CEO, Director · Jun 20, 2018 – Feb 8, 2023 · Past |
| Azadeh Golipour | Chief Technology Officer · Feb 1, 2024 – Feb 1, 2024 · Past |
| Christopher Paige | Director · Jun 20, 2018 – Jun 6, 2023 · Past |
| Essra Ridha | Chief Medical Officer · Oct 19, 2021 – Feb 1, 2024 · Past |
| Jessica Chutter | Director · Since at least Apr 23, 2026 |
| Marc Schwabish | Chief Business Officer · Since at least Jun 20, 2024 |
| Peter McNamara | Chief Scientific Officer · Since at least Jun 30, 2026 |
Log in to ask 6ix AI your own questions about Tectonic Therapeutic, Inc.